Skip to main content
Erschienen in: Abdominal Radiology 7/2017

15.02.2017

Parametric response mapping of dynamic CT: enhanced prediction of survival in hepatocellular carcinoma patients treated with transarterial chemoembolization

verfasst von: Seung Joon Choi, Jonghoon Kim, Hyung Sik Kim, Hyunjin Park

Erschienen in: Abdominal Radiology | Ausgabe 7/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The aim of this study was to evaluate the prognostic significance of parametric response mapping (PRM) analysis for hepatocellular carcinoma (HCC) patients undergoing transarterial chemoembolization (TACE).

Methods

We recruited 65 HCC patients who underwent TACE. These patients underwent longitudinal multiphasic CT before and after TACE. We applied PRM analysis to the baseline CT before TACE and first/second follow-up CTs. The results of PRM analyses were used to stratify patients into responders and non-responders. Overall survival was compared between the two groups. An independent survival analysis using conventional radiological assessments was performed, and the results were compared with PRM results. Univariate and multivariate analyses were performed to identify clinical factors affecting survival.

Results

The PRM analyses demonstrated that the responding group had a median survival of 529 days, while the non-responding group had a median survival of 263 days [hazard ratio (HR) 12.9, p < 0.05 for differences in survival]. The manual analyses indicated median survivals of 491 and 329 days for the responding and non-responding groups, respectively (HR 2.7, p < 0.05). Tumor size, albumin level, and PRM values were found to be significantly related to overall survival after univariate and multivariate analyses.

Conclusions

The PRM analysis could be a better predictor of overall survival for patients with HCC undergoing TACE than conventional radiological assessments.
Literatur
1.
Zurück zum Zitat Bosch FX, Ribes J, Díaz M, Cléries R (2004) Primary liver cancer: worldwide incidence and trends. Gastroenterology 127(5):S5–S16CrossRefPubMed Bosch FX, Ribes J, Díaz M, Cléries R (2004) Primary liver cancer: worldwide incidence and trends. Gastroenterology 127(5):S5–S16CrossRefPubMed
2.
Zurück zum Zitat Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55(2):74–108CrossRefPubMed Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55(2):74–108CrossRefPubMed
3.
Zurück zum Zitat Jarnagin WR, Gonen M, Fong Y, et al. (2002) Improvement in perioperative outcome after hepatic resection: analysis of 1803 consecutive cases over the past decade. Ann Surg 236(4):397–406 ((Discussion 406–407))CrossRefPubMedPubMedCentral Jarnagin WR, Gonen M, Fong Y, et al. (2002) Improvement in perioperative outcome after hepatic resection: analysis of 1803 consecutive cases over the past decade. Ann Surg 236(4):397–406 ((Discussion 406–407))CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Bruix J, Sala M, Llovet JM (2004) Chemoembolization for hepatocellular carcinoma. Gastroenterology 127(5):S179–S188CrossRefPubMed Bruix J, Sala M, Llovet JM (2004) Chemoembolization for hepatocellular carcinoma. Gastroenterology 127(5):S179–S188CrossRefPubMed
5.
Zurück zum Zitat Llovet JM, Real MI, Montaña X, et al. (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359(9319):1734–1739CrossRefPubMed Llovet JM, Real MI, Montaña X, et al. (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359(9319):1734–1739CrossRefPubMed
6.
Zurück zum Zitat Llovet JM, Bruix J (2003) Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37(2):429–442CrossRefPubMed Llovet JM, Bruix J (2003) Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37(2):429–442CrossRefPubMed
7.
Zurück zum Zitat Cammà C, Schepis F, Orlando A, et al. (2002) Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 224:47–54CrossRefPubMed Cammà C, Schepis F, Orlando A, et al. (2002) Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 224:47–54CrossRefPubMed
8.
Zurück zum Zitat Mabed M, Esmaeel M, El-Khodary T, Awad M, Amer T (2009) A randomized controlled trial of transcatheter arterial chemoembolization with lipiodol, doxorubicin and cisplatin versus intravenous doxorubicin for patients with unresectable hepatocellular carcinoma. Eur J Cancer Care 18(5):492–499CrossRef Mabed M, Esmaeel M, El-Khodary T, Awad M, Amer T (2009) A randomized controlled trial of transcatheter arterial chemoembolization with lipiodol, doxorubicin and cisplatin versus intravenous doxorubicin for patients with unresectable hepatocellular carcinoma. Eur J Cancer Care 18(5):492–499CrossRef
9.
Zurück zum Zitat Ahsun R, Miller FH, Kulik LM, et al. (2010) Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma. J Am Med Assoc 303(11):1062–1069CrossRef Ahsun R, Miller FH, Kulik LM, et al. (2010) Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma. J Am Med Assoc 303(11):1062–1069CrossRef
10.
Zurück zum Zitat Keppke AL, Salem R, Reddy D, et al. (2007) Imaging of hepatocellular carcinoma after treatment with Yttrium-90 microspheres. Am J Roentgenol 188(3):768–775CrossRef Keppke AL, Salem R, Reddy D, et al. (2007) Imaging of hepatocellular carcinoma after treatment with Yttrium-90 microspheres. Am J Roentgenol 188(3):768–775CrossRef
11.
Zurück zum Zitat Gillmore R, Stuart S, Kirkwood A, et al. (2011) EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. J Hepatol 55(6):1309–1316CrossRefPubMed Gillmore R, Stuart S, Kirkwood A, et al. (2011) EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. J Hepatol 55(6):1309–1316CrossRefPubMed
12.
Zurück zum Zitat Kim BK, Kim KA, Park JY, et al. (2013) Prospective comparison of prognostic values of modified response evaluation criteria in solid tumours with european association for the study of the liver criteria in hepatocellular carcinoma following chemoembolisation. Eur J Cancer 49(4):826–834CrossRefPubMed Kim BK, Kim KA, Park JY, et al. (2013) Prospective comparison of prognostic values of modified response evaluation criteria in solid tumours with european association for the study of the liver criteria in hepatocellular carcinoma following chemoembolisation. Eur J Cancer 49(4):826–834CrossRefPubMed
13.
Zurück zum Zitat Suzuki C, Torkzad MR, Jacobsson H, et al. (2010) Interobserver and intraobserver variability in the response evaluation of cancer therapy according to RECIST and WHO-criteria. Acta Oncol 49(4):509–514CrossRefPubMed Suzuki C, Torkzad MR, Jacobsson H, et al. (2010) Interobserver and intraobserver variability in the response evaluation of cancer therapy according to RECIST and WHO-criteria. Acta Oncol 49(4):509–514CrossRefPubMed
14.
Zurück zum Zitat Lencioni R, Llovet JM (2013) Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Clin Cancer Res 19(6):1312–1314CrossRefPubMed Lencioni R, Llovet JM (2013) Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Clin Cancer Res 19(6):1312–1314CrossRefPubMed
15.
Zurück zum Zitat Forner A, Ayuso C, Varela M, et al. (2009) Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer 115:616–623CrossRefPubMed Forner A, Ayuso C, Varela M, et al. (2009) Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer 115:616–623CrossRefPubMed
16.
Zurück zum Zitat Llovet JM, Mazzaferro V, Hilgard P, et al. (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390CrossRefPubMed Llovet JM, Mazzaferro V, Hilgard P, et al. (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390CrossRefPubMed
17.
Zurück zum Zitat Galbán CJ, Chenevert TL, Meyer CR, et al. (2009) The parametric response map is an imaging biomarker for early cancer treatment outcome. Nat Med 15(5):572–576CrossRefPubMedPubMedCentral Galbán CJ, Chenevert TL, Meyer CR, et al. (2009) The parametric response map is an imaging biomarker for early cancer treatment outcome. Nat Med 15(5):572–576CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Galbán CJ, Mukherji SK, Chenevert TL, et al. (2009) A feasibility study of parametric response map analysis of diffusion-weighted magnetic resonance imaging scans of head and neck cancer patients for providing early detection of therapeutic efficacy. Transl Oncol 2(3):184–190CrossRefPubMedPubMedCentral Galbán CJ, Mukherji SK, Chenevert TL, et al. (2009) A feasibility study of parametric response map analysis of diffusion-weighted magnetic resonance imaging scans of head and neck cancer patients for providing early detection of therapeutic efficacy. Transl Oncol 2(3):184–190CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Kim MM, Lawrence TS, Cao Y (2015) Advances in magnetic resonance and positron emission tomography imaging: assessing response in the treatment of low-grade glioma. Semin Radiat Oncol 25(3):172–180CrossRefPubMedPubMedCentral Kim MM, Lawrence TS, Cao Y (2015) Advances in magnetic resonance and positron emission tomography imaging: assessing response in the treatment of low-grade glioma. Semin Radiat Oncol 25(3):172–180CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Galbán CJ, Han MK, Boes JL, et al. (2012) Computed tomography-based biomarker provides unique signature for diagnosis of COPD phenotypes and disease progression. Nat Med 18(11):1711–1715CrossRefPubMedPubMedCentral Galbán CJ, Han MK, Boes JL, et al. (2012) Computed tomography-based biomarker provides unique signature for diagnosis of COPD phenotypes and disease progression. Nat Med 18(11):1711–1715CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Boes JL, Hoff BA, Hylton N, et al. (2014) Image registration for quantitative parametric response mapping of cancer treatment response. Transl Oncol 7(1):101–110CrossRefPubMedPubMedCentral Boes JL, Hoff BA, Hylton N, et al. (2014) Image registration for quantitative parametric response mapping of cancer treatment response. Transl Oncol 7(1):101–110CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Choi SJ, Kim J, Seo J, et al. (2014) Parametric response mapping of dynamic CT as an imaging biomarker to distinguish viability of hepatocellular carcinoma treated with transcatheter arterial chemoembolization. Abdom Imaging 39(3):518–525CrossRefPubMed Choi SJ, Kim J, Seo J, et al. (2014) Parametric response mapping of dynamic CT as an imaging biomarker to distinguish viability of hepatocellular carcinoma treated with transcatheter arterial chemoembolization. Abdom Imaging 39(3):518–525CrossRefPubMed
23.
Zurück zum Zitat Choi SJ, Kim J, Seo J, et al. (2015) Parametric response mapping of dynamic CT for predicting intrahepatic recurrence of hepatocellular carcinoma after conventional transcatheter arterial chemoembolization. Eur Radiol 26:225–234CrossRefPubMed Choi SJ, Kim J, Seo J, et al. (2015) Parametric response mapping of dynamic CT for predicting intrahepatic recurrence of hepatocellular carcinoma after conventional transcatheter arterial chemoembolization. Eur Radiol 26:225–234CrossRefPubMed
24.
Zurück zum Zitat Dufour JF, Greten TF, Raymond E, et al. (2012) EASL–EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 56(4):908–943CrossRef Dufour JF, Greten TF, Raymond E, et al. (2012) EASL–EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 56(4):908–943CrossRef
26.
Zurück zum Zitat Terzi E, Golfieri R, Piscaglia F, et al. (2012) Response rate and clinical outcome of HCC after first and repeated cTACE performed “on demand”. J Hepatol 57(6):1258–1267CrossRefPubMed Terzi E, Golfieri R, Piscaglia F, et al. (2012) Response rate and clinical outcome of HCC after first and repeated cTACE performed “on demand”. J Hepatol 57(6):1258–1267CrossRefPubMed
27.
Zurück zum Zitat Kim BK, Kim SU, Kim MJ, et al. (2013) Number of target lesions for EASL and modified RECIST to predict survivals in hepatocellular carcinoma treated with chemoembolization. Clin Cancer Res 19:1503–1511CrossRefPubMed Kim BK, Kim SU, Kim MJ, et al. (2013) Number of target lesions for EASL and modified RECIST to predict survivals in hepatocellular carcinoma treated with chemoembolization. Clin Cancer Res 19:1503–1511CrossRefPubMed
28.
Zurück zum Zitat Shim JH, Lee HC, Won HJ, et al. (2012) Maximum number of target lesions required to measure responses to transarterial chemoembolization using the enhancement criteria in patients with intrahepatic hepatocellular carcinoma. J Hepatol 56:406–411CrossRefPubMed Shim JH, Lee HC, Won HJ, et al. (2012) Maximum number of target lesions required to measure responses to transarterial chemoembolization using the enhancement criteria in patients with intrahepatic hepatocellular carcinoma. J Hepatol 56:406–411CrossRefPubMed
29.
Zurück zum Zitat Jung ES, Kim JHJS, Yoon EL, et al. (2013) Comparison of the methods for tumor response assessment in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. J Hepatol 58(6):1181–1187CrossRefPubMed Jung ES, Kim JHJS, Yoon EL, et al. (2013) Comparison of the methods for tumor response assessment in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. J Hepatol 58(6):1181–1187CrossRefPubMed
30.
Zurück zum Zitat Meyer CR, Boes JL, Kim B, et al. (1997) Demonstration of accuracy and clinical versatility of mutual information for automatic multimodality image fusion using affine and thin-plate spline warped geometric deformations. Med Image Anal 1(3):195–206CrossRefPubMed Meyer CR, Boes JL, Kim B, et al. (1997) Demonstration of accuracy and clinical versatility of mutual information for automatic multimodality image fusion using affine and thin-plate spline warped geometric deformations. Med Image Anal 1(3):195–206CrossRefPubMed
31.
Zurück zum Zitat Georgiades C, Geschwind J-F, Harrison N, et al. (2012) Lack of response after initial chemoembolization for hepatocellular carcinoma: does it predict failure of subsequent treatment? Radiology 265(1):115–123CrossRefPubMedPubMedCentral Georgiades C, Geschwind J-F, Harrison N, et al. (2012) Lack of response after initial chemoembolization for hepatocellular carcinoma: does it predict failure of subsequent treatment? Radiology 265(1):115–123CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Shim JH, Lee HC, Kim S-O, et al. (2012) Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models. Radiology 262(2):708–718CrossRefPubMed Shim JH, Lee HC, Kim S-O, et al. (2012) Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models. Radiology 262(2):708–718CrossRefPubMed
33.
Zurück zum Zitat Kim SH, Lee WJ, Lim HK, Lim JH (2007) Prediction of viable tumor in hepatocellular carcinoma treated with transcatheter arterial chemoembolization: usefulness of attenuation value measurement at quadruple-phase helical computed tomography. J Comput Assist Tomogr 31(2):198–203CrossRefPubMed Kim SH, Lee WJ, Lim HK, Lim JH (2007) Prediction of viable tumor in hepatocellular carcinoma treated with transcatheter arterial chemoembolization: usefulness of attenuation value measurement at quadruple-phase helical computed tomography. J Comput Assist Tomogr 31(2):198–203CrossRefPubMed
34.
Zurück zum Zitat Hunt SJ, Yu W, Weintraub J, Prince MR, Kothary N (2009) Radiologic monitoring of hepatocellular carcinoma tumor viability after transhepatic arterial chemoembolization: estimating the accuracy of contrast-enhanced cross-sectional imaging with histopathologic correlation. J Vasc Interv Radiol 20(1):30–38CrossRefPubMed Hunt SJ, Yu W, Weintraub J, Prince MR, Kothary N (2009) Radiologic monitoring of hepatocellular carcinoma tumor viability after transhepatic arterial chemoembolization: estimating the accuracy of contrast-enhanced cross-sectional imaging with histopathologic correlation. J Vasc Interv Radiol 20(1):30–38CrossRefPubMed
35.
Zurück zum Zitat Lin MingDe, Pellerin Olivier, Bhagat Nikhil, et al. (2012) Quantitative and volumetric EASL and RECIST: feasibility of a semi-automated software method to assess tumor response after transcatheter arterial chemoembolization (TACE). J Vasc Interv Radiol 23(12):1629–1637CrossRefPubMedPubMedCentral Lin MingDe, Pellerin Olivier, Bhagat Nikhil, et al. (2012) Quantitative and volumetric EASL and RECIST: feasibility of a semi-automated software method to assess tumor response after transcatheter arterial chemoembolization (TACE). J Vasc Interv Radiol 23(12):1629–1637CrossRefPubMedPubMedCentral
36.
Zurück zum Zitat Bargellini I, Scionti A, Mismas V, et al. (2014) Identification of responders to sorafenib in hepatocellular carcinoma: is tumor volume measurement the way forward? Oncology 86(4):191–198CrossRefPubMed Bargellini I, Scionti A, Mismas V, et al. (2014) Identification of responders to sorafenib in hepatocellular carcinoma: is tumor volume measurement the way forward? Oncology 86(4):191–198CrossRefPubMed
37.
Zurück zum Zitat Mannelli L, Kim S, Hajdu CH, et al. (2009) Assessment of tumor necrosis of hepatocellular carcinoma after chemoembolization: diffusion-weighted and contrast-enhanced MRI with histopathologic correlation of the explanted liver. Am J Roentgenol 193(4):1044–1052CrossRef Mannelli L, Kim S, Hajdu CH, et al. (2009) Assessment of tumor necrosis of hepatocellular carcinoma after chemoembolization: diffusion-weighted and contrast-enhanced MRI with histopathologic correlation of the explanted liver. Am J Roentgenol 193(4):1044–1052CrossRef
38.
Zurück zum Zitat Kim S, Mannelli L, Hajdu CH, et al. (2010) Hepatocellular carcinoma: assessment of response to transarterial chemoembolization with image subtraction. J Magn Reson Imaging 31(2):348–355CrossRefPubMed Kim S, Mannelli L, Hajdu CH, et al. (2010) Hepatocellular carcinoma: assessment of response to transarterial chemoembolization with image subtraction. J Magn Reson Imaging 31(2):348–355CrossRefPubMed
39.
Zurück zum Zitat Rossi S, Garbagnati F, Lencioni R, et al. (2000) Percutaneous radio-frequency thermal ablation of nonresectable hepatocellular carcinoma after occlusion of tumor blood supply. Radiology 217(1):119–126CrossRefPubMed Rossi S, Garbagnati F, Lencioni R, et al. (2000) Percutaneous radio-frequency thermal ablation of nonresectable hepatocellular carcinoma after occlusion of tumor blood supply. Radiology 217(1):119–126CrossRefPubMed
40.
Zurück zum Zitat Shim SJ, Seong J, Han KH, et al. (2005) Local radiotherapy as a complement to incomplete transcatheter arterial chemoembolization in locally advanced hepatocellular carcinoma. Liver Int 25(6):1189–1196CrossRefPubMed Shim SJ, Seong J, Han KH, et al. (2005) Local radiotherapy as a complement to incomplete transcatheter arterial chemoembolization in locally advanced hepatocellular carcinoma. Liver Int 25(6):1189–1196CrossRefPubMed
41.
Zurück zum Zitat Hinrichs J, Shin H, Vogel A, et al. (2016) Parametric response mapping of contrast-enhanced biphasic CT for evaluating tumour viability of hepatocellular carcinoma after TACE. Eur Radiol . doi:10.1007/s00330-015-4203-4 Hinrichs J, Shin H, Vogel A, et al. (2016) Parametric response mapping of contrast-enhanced biphasic CT for evaluating tumour viability of hepatocellular carcinoma after TACE. Eur Radiol . doi:10.​1007/​s00330-015-4203-4
42.
Zurück zum Zitat Vilgrain V (2010) Advancement in HCC imaging: diagnosis, staging and treatment efficacy assessments. Hepatocellular carcinoma: Imaging in assessing treatment efficacy. J Hepatobiliary Pancreat Sci 17:374–379CrossRefPubMed Vilgrain V (2010) Advancement in HCC imaging: diagnosis, staging and treatment efficacy assessments. Hepatocellular carcinoma: Imaging in assessing treatment efficacy. J Hepatobiliary Pancreat Sci 17:374–379CrossRefPubMed
Metadaten
Titel
Parametric response mapping of dynamic CT: enhanced prediction of survival in hepatocellular carcinoma patients treated with transarterial chemoembolization
verfasst von
Seung Joon Choi
Jonghoon Kim
Hyung Sik Kim
Hyunjin Park
Publikationsdatum
15.02.2017
Verlag
Springer US
Erschienen in
Abdominal Radiology / Ausgabe 7/2017
Print ISSN: 2366-004X
Elektronische ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-017-1082-y

Weitere Artikel der Ausgabe 7/2017

Abdominal Radiology 7/2017 Zur Ausgabe

Classics in Abdominal Imaging

Apple core sign in colorectal cancer

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

S3-Leitlinie zu Pankreaskrebs aktualisiert

23.04.2024 Pankreaskarzinom Nachrichten

Die Empfehlungen zur Therapie des Pankreaskarzinoms wurden um zwei Off-Label-Anwendungen erweitert. Und auch im Bereich der Früherkennung gibt es Aktualisierungen.

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

18.04.2024 Pädiatrische Notfallmedizin Nachrichten

Im Choosing-Wisely-Programm, das für die deutsche Initiative „Klug entscheiden“ Pate gestanden hat, sind erstmals Empfehlungen zum Umgang mit Notfällen von Kindern erschienen. Fünf Dinge gilt es demnach zu vermeiden.

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.